Skip to main content

Table 3 Baseline clinical and laboratory features

From: Safety and efficacy of hydroxychloroquine for treatment of non-severe COVID-19 among adults in Uganda: a randomized open label phase II clinical trial

Characteristics Arm 1:
HCQ + SOC
Arm 2:
SOC alone
Total
Number randomized 55 50 105
Body mass index (BMI) in kgs/m2 a    
 Number of observations 55 49 104
 Mean (standard deviation) 30.8 (7.5) 31.3 (7.3) 31.0 (7.4)
 BMI categories    
  < 18.5 1 (1.8) 1 (2.0) 2 (1.9)
  18.5 to < 25 (normal) 13 (23.6) 9 (18.4) 22 (21.2)
  25 to < 30 (over-weight) 14 (25.5) 12 (24.5) 26 (25.0)
  ≥ 30 (obese) 27 (49.1) 27 (55.1) 54 (51.9)
ECG QTc interval (ms)    
 Overall–mean (SD) 417 (22) 409 (20) 413 (22)
 Males–mean(SD) 410 (22) 404 (19) 407 (21)
 Females–mean(SD) 430 (15) 423 (16) 427 (16)
Serum Potassium (mmols/L)    
 Number of observations 52 41 93
 Mean (SD) 4.6 (0.9) 4.6 (0.7) 4.6 (0.8)
Visual color test, (%)    
 Normal 54 (94.7) 50 (100.0) 104 (97.2)
 Abnormal 3 (5.3) 0 3 (2.8)
Pulse rate (beats/min), median (IQR) 78 (70–86) 78 (67–85) 78 (68–86)
Visual acuity–left eye, n (%)    
 6/6 42 (76.4) 37 (77.1) 79 (76.7)
 5/6 4 (7.3) 1 (2.1) 5 (4.9)
 4/6 2 (3.6) 0 2 (1.9)
 20/30 6 (10.9) 8 (16.7) 14 (13.6)
 6/12 1 (1.8) 1 (2.1) 2 (1.9)
 6/18 0 1 (2.1) 1 (1.0)
Visual acuity–right eye, n (%)    
 6/6 43 (75.4) 38 (82.6) 81 (78.6)
 5/6 5 (8.8) 0 5 4.9)
 4/6 2 (3.5) 1 (2.2) 3 (2.9)
 6/12 0 1 (2.2) 1 (1.0)
 20/30 7 (12.3) 6 (13.0) 13 (12.6)
  1. aMissing values: BMI, 1 (0.95%)